Groundbreaking Clinical Study Reveals Promising Evidence for VIVAZEN®'s Kratom Extracts

VIVAZEN® announces results of a 28-day clinical trial evaluating the safety and tolerability of its proprietary kratom extracts.

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

VIVAZEN®, a botanical wellness company, has announced the results of a pioneering 28-day clinical study evaluating the safety and tolerability of its proprietary kratom extracts. The findings, presented at the University of Florida Fifth Scientific Kratom Symposium, showed no severe adverse events during the trial period, marking a significant step in understanding the safety profile of kratom extracts at low doses.

Why it matters

This research contributes to the growing body of medical and scientific evidence supporting the potential health and wellness benefits of kratom for adults. The study's findings could help inform policy decisions and empower consumers to make informed choices about botanical wellness products.

The details

The clinical study, led by principal investigator Dr. Paula Brown, Director of Applied Research at the BC Institute of Technology and Adjunct Professor at the University of Illinois Chicago, assessed the effects of VIVAZEN®'s proprietary kratom extract on adult participants over a 28-day period. The study reported that the kratom extracts were well-tolerated, with no observed severe adverse events or evidence of dependence or withdrawal.

  • The 28-day clinical study was conducted in 2026.
  • The study results were presented at the University of Florida Fifth Scientific Kratom Symposium on February 19, 2026.

The players

VIVAZEN®

A botanical wellness company that has delivered trusted, high-quality botanical supplements for over a decade.

Dr. Paula Brown

The principal investigator of the clinical study, and the Director of Applied Research at the BC Institute of Technology and Adjunct Professor at the University of Illinois Chicago.

Got photos? Submit your photos here. ›

What they’re saying

“Policy should be informed by scientific evidence, not fear-based assumptions.”

— Dr. Paula Brown, Principal Investigator (Business Wire)

“Consumers rely on and, frankly, deserve transparency and robust safety standards to make informed decisions about their wellness. Our hope is that studies like this will help guide policy decisions that acknowledge the potential benefits of kratom while prioritizing consumer safety.”

— Dr. Paula Brown, Principal Investigator (Business Wire)

What’s next

The U.S. Food and Drug Administration has initiated human trials on kratom, reflecting continued scientific interest in further understanding kratom's safety and pharmacology.

The takeaway

This clinical study marks a significant step in understanding the safety profile of kratom extracts and contributes to the growing body of research supporting the potential health and wellness benefits of kratom for adults. The findings could help inform policy decisions and empower consumers to make informed choices about botanical wellness products.